Abstract
Aim: To show the safety and clinical usefulness of IRE. Methods: A total of 23 pancreatic adeno-carcinomas, two liver mets of colorectal carcinoma and 1 renal adeno carcinoma have undergone IRE percutaneously under CT control or during laparotomy with US guidance.
Results: IRE is safe method, 30 days mortality 0. There is no significant prolongation of survival in the group of unresectable pancreatic cancer.
Survival in the group of pancreatic cancer is 10 months. Conclusion: IRE is a safe and useful ablative method, especially with the tumors nearby critical structures.